Investor FAQ

Q: Who is NervGen’s transfer agent and registrar?

NervGen’s transfer agent is: Computershare Investor Services Inc. 510 Burrard Street, 3rd Floor Vancouver, BC V6C 3B9 T: (604) 661-9400

Q: Who is NervGen's auditor?

NervGen’s auditor is: KPMG LLP Pacific Centre 777 Dunsmuir Street, P.O. Box 10426 Vancouver, BC V7Y 1K3

Q: What are the CUSIP and ISIN numbers for NervGen?

CUSIP #: 64082X203 ISIN #: CA64082X2032

Most frequently asked questions and answers

Where is NervGen's stock listed?

NervGen trades in Canada on the TSX.V under the symbol NGEN and in the U.S. on the OTCQB under the symbol NGENF.

How many NervGen shares are issued and outstanding?

Refer to NervGen’s latest filed financial statements for the latest available share information.

When is NervGen's fiscal year end?

NervGen’s fiscal year end is December 31st.

Who is NervGen’s transfer agent and registrar?

NervGen’s transfer agent is:

Computershare Investor Services Inc.

510 Burrard Street, 3rd Floor
Vancouver, BC V6C 3B9

T: (604) 661-9400

Who is NervGen's auditor?

NervGen’s auditor is:

KPMG LLP

Pacific Centre
777 Dunsmuir Street, P.O. Box 10426
Vancouver, BC V7Y 1K3

What are the CUSIP and ISIN numbers for NervGen?

CUSIP #: 64082X203
ISIN #: CA64082X2032

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: info@nervgen.com

Subscribe for Updates